Company Overview
An Open and Socially Responsible Healthcare Group
Company Overview
OSR Holdings, an Open and Socially Responsible Healthcare Group
With headquarters and operations spanning the US, Europe, and Korea, our hub-and-spoke model leverages centralized expertise to support a portfolio of innovative subsidiaries. Our people bring a rare mix of deep scientific knowledge, clinical insight, and capital markets experience, enabling disciplined, high-impact decision-making. United by a focus on “simplification through innovation,” we streamline complex therapies, delivery systems, and healthcare processes to make advanced treatments more accessible, efficient, and effective for patients and healthcare systems worldwide.
Learn more about our team here
With headquarters and operations spanning the US, Europe, and Korea, our hub-and-spoke model leverages centralized expertise to support a portfolio of innovative subsidiaries. Our people bring a rare mix of deep scientific knowledge, clinical insight, and capital markets experience, enabling disciplined, high-impact decision-making. United by a focus on “simplification through innovation,” we streamline complex therapies, delivery systems, and healthcare processes to make advanced treatments more accessible, efficient, and effective for patients and healthcare systems worldwide.
Strategic Portfolio Expansion
At OSR Holdings, we target biopharmaceuticals that have innovative, proprietary R&D platforms, rather than single assets. By taking 100% ownership in our spoke companies, we maintain full operational and strategic control.
We constantly evaluate M&A opportunities that advance innovative healthcare, whether through addressing unmet patient needs or lowering patient costs and burden. We are focused on portfolio expansion across the U.S., Europe, and Korea. Our platforms currently include:
Immuno-Oncology: Development of oral T-cell activation therapies targeting tumor vasculature and associated structures.
Regenerative Biologics: Design-Augmented (DA) biologics aimed at treating age-related and degenerative diseases.
Noninvasive Glucose Monitoring: A pioneering, truly noninvasive glucose monitor based on NIRS technology.
Medical Device Technologies: Distribution of neurovascular intervention systems in South Korea.
Strategic Portfolio Expansion
At OSR Holdings, we target biopharmaceuticals that have innovative, proprietary R&D platforms, rather than single assets. By taking 100% ownership in our spoke companies, we maintain full operational and strategic control.
We constantly evaluate M&A opportunities that advance innovative healthcare, whether through addressing unmet patient needs or lowering patient costs and burden. We are focused on portfolio expansion across the U.S., Europe, and Korea. Our platforms currently include:
Immuno-Oncology: Development of oral T-cell activation therapies targeting tumor vasculature and associated structures.
Regenerative Biologics: Design-Augmented (DA) biologics aimed at treating age-related and degenerative diseases.
Noninvasive Glucose Monitoring: A pioneering, truly noninvasive glucose monitor based on NIRS technology.
Medical Device Technologies: Distribution of neurovascular intervention systems in South Korea.
OSR Holdings Reg No. 589-86-01485
Email. group@osr-holdings.com
US: 10900 NE 4th Street, 2300 Bellevue, WA 98004
KR: B-dong, 3F, 37-36 Hoedong-gil, Paju-si, Gyeonggi-do
CH: Technologiepark Basel, Hochbergerstrasse 60c
Copyright © OSR Holdings, Inc. All Rights Reserved.
OSR Holdings, Inc. Reg No. 589-86-01485 Email. group@osr-holdings.com
U.S 10900 NE 4th Street, 2300 Bellevue, WA 98004
Korea, Republic of B-dong, 3F, 37-36 Hoedong-gil, Paju-si, Gyeonggi-do
Switzerland Technologiepark Basel, Hochbergerstrasse 60c, CH-4057
Copyright © OSR Holdings, Inc. All Rights Reserved.
